vs
Ginkgo Bioworks Holdings, Inc.（DNA）与花花公子（PLBY）财务数据对比。点击上方公司名可切换其他公司
花花公子的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.0倍（$34.9M vs $33.4M），花花公子同比增速更快（4.2% vs -23.8%），花花公子自由现金流更多（$1.1M vs $-47.7M），过去两年花花公子的营收复合增速更高（11.0% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
花花公子集团（Playboy, Inc.）起源于1953年由休·海夫纳联合合伙人在美国芝加哥创立，初始部分资金来自海夫纳母亲提供的1000美元贷款，是美国知名生活方式与娱乐内容品牌，旗下核心《花花公子》杂志同时发行电子版与纸质版。
DNA vs PLBY — 直观对比
营收规模更大
PLBY
是对方的1.0倍
$33.4M
营收增速更快
PLBY
高出28.1%
-23.8%
自由现金流更多
PLBY
多$48.8M
$-47.7M
两年增速更快
PLBY
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $34.9M |
| 净利润 | — | $3.6M |
| 毛利率 | — | 73.3% |
| 营业利润率 | -211.9% | 7.9% |
| 净利率 | — | 10.3% |
| 营收同比 | -23.8% | 4.2% |
| 净利润同比 | — | 128.6% |
| 每股收益（稀释后） | $-1.41 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAPLBY
| Q4 25 | $33.4M | $34.9M | ||
| Q3 25 | $38.8M | $29.0M | ||
| Q2 25 | $49.6M | $28.1M | ||
| Q1 25 | $48.3M | $28.9M | ||
| Q4 24 | $43.8M | $33.5M | ||
| Q3 24 | $89.0M | $29.4M | ||
| Q2 24 | $56.2M | $24.9M | ||
| Q1 24 | $37.9M | $28.3M |
净利润DNAPLBY
| Q4 25 | — | $3.6M | ||
| Q3 25 | $-80.8M | $460.0K | ||
| Q2 25 | $-60.3M | $-7.7M | ||
| Q1 25 | $-91.0M | $-9.0M | ||
| Q4 24 | — | $-12.5M | ||
| Q3 24 | $-56.4M | $-33.8M | ||
| Q2 24 | $-217.2M | $-16.7M | ||
| Q1 24 | $-165.9M | $-16.4M |
毛利率DNAPLBY
| Q4 25 | — | 73.3% | ||
| Q3 25 | — | 76.0% | ||
| Q2 25 | — | 65.4% | ||
| Q1 25 | — | 68.6% | ||
| Q4 24 | — | 70.8% | ||
| Q3 24 | — | 61.0% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 55.8% |
营业利润率DNAPLBY
| Q4 25 | -211.9% | 7.9% | ||
| Q3 25 | -231.8% | 4.7% | ||
| Q2 25 | -132.1% | -20.9% | ||
| Q1 25 | -184.1% | -21.7% | ||
| Q4 24 | -236.3% | -13.3% | ||
| Q3 24 | -62.0% | -96.0% | ||
| Q2 24 | -396.7% | -37.0% | ||
| Q1 24 | -469.1% | -31.5% |
净利率DNAPLBY
| Q4 25 | — | 10.3% | ||
| Q3 25 | -207.9% | 1.6% | ||
| Q2 25 | -121.6% | -27.3% | ||
| Q1 25 | -188.2% | -31.3% | ||
| Q4 24 | — | -37.4% | ||
| Q3 24 | -63.3% | -114.7% | ||
| Q2 24 | -386.4% | -66.9% | ||
| Q1 24 | -437.3% | -58.1% |
每股收益（稀释后）DNAPLBY
| Q4 25 | $-1.41 | $0.05 | ||
| Q3 25 | $-1.45 | $0.00 | ||
| Q2 25 | $-1.10 | $-0.08 | ||
| Q1 25 | $-1.68 | $-0.10 | ||
| Q4 24 | $-1.91 | $-0.13 | ||
| Q3 24 | $-1.08 | $-0.45 | ||
| Q2 24 | $-4.23 | $-0.23 | ||
| Q1 24 | $-3.32 | $-0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $37.8M |
| 总债务越低越好 | — | $174.2M |
| 股东权益账面价值 | $508.6M | $18.4M |
| 总资产 | $1.1B | $292.4M |
| 负债/权益比越低杠杆越低 | — | 9.48× |
8季度趋势，按日历期对齐
现金及短期投资DNAPLBY
| Q4 25 | $422.6M | $37.8M | ||
| Q3 25 | $495.5M | $27.5M | ||
| Q2 25 | $559.4M | $19.6M | ||
| Q1 25 | $325.3M | $23.7M | ||
| Q4 24 | $561.6M | $30.9M | ||
| Q3 24 | $616.2M | $9.5M | ||
| Q2 24 | $730.4M | $16.9M | ||
| Q1 24 | $840.4M | $19.0M |
总债务DNAPLBY
| Q4 25 | — | $174.2M | ||
| Q3 25 | — | $176.8M | ||
| Q2 25 | — | $177.5M | ||
| Q1 25 | — | $176.3M | ||
| Q4 24 | — | $176.6M | ||
| Q3 24 | — | $200.0M | ||
| Q2 24 | — | $196.3M | ||
| Q1 24 | — | $193.4M |
股东权益DNAPLBY
| Q4 25 | $508.6M | $18.4M | ||
| Q3 25 | $559.8M | $3.8M | ||
| Q2 25 | $613.0M | $-17.5M | ||
| Q1 25 | $647.4M | $-11.4M | ||
| Q4 24 | $716.1M | $-7.7M | ||
| Q3 24 | $797.9M | $-15.7M | ||
| Q2 24 | $833.1M | $15.7M | ||
| Q1 24 | $987.3M | $29.5M |
总资产DNAPLBY
| Q4 25 | $1.1B | $292.4M | ||
| Q3 25 | $1.2B | $278.3M | ||
| Q2 25 | $1.2B | $264.1M | ||
| Q1 25 | $1.3B | $270.6M | ||
| Q4 24 | $1.4B | $284.7M | ||
| Q3 24 | $1.5B | $271.5M | ||
| Q2 24 | $1.6B | $301.8M | ||
| Q1 24 | $1.6B | $309.1M |
负债/权益比DNAPLBY
| Q4 25 | — | 9.48× | ||
| Q3 25 | — | 46.86× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.51× | ||
| Q1 24 | — | 6.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $1.4M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $1.1M |
| 自由现金流率自由现金流/营收 | -142.8% | 3.2% |
| 资本支出强度资本支出/营收 | 0.0% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 0.39× |
| 过去12个月自由现金流最近4个季度 | — | $-1.0M |
8季度趋势，按日历期对齐
经营现金流DNAPLBY
| Q4 25 | $-47.7M | $1.4M | ||
| Q3 25 | $-31.6M | $10.1M | ||
| Q2 25 | $-40.3M | $-3.9M | ||
| Q1 25 | $-51.5M | $-7.6M | ||
| Q4 24 | $-42.4M | $161.0K | ||
| Q3 24 | $-103.5M | $-6.5M | ||
| Q2 24 | $-84.4M | $-3.0M | ||
| Q1 24 | $-89.3M | $-9.8M |
自由现金流DNAPLBY
| Q4 25 | $-47.7M | $1.1M | ||
| Q3 25 | — | $9.8M | ||
| Q2 25 | $-40.3M | $-4.3M | ||
| Q1 25 | $-59.1M | $-7.7M | ||
| Q4 24 | $-56.1M | $-401.0K | ||
| Q3 24 | $-118.6M | $-7.0M | ||
| Q2 24 | $-111.4M | $-3.7M | ||
| Q1 24 | $-96.0M | $-10.3M |
自由现金流率DNAPLBY
| Q4 25 | -142.8% | 3.2% | ||
| Q3 25 | — | 33.8% | ||
| Q2 25 | -81.2% | -15.2% | ||
| Q1 25 | -122.4% | -26.5% | ||
| Q4 24 | -128.0% | -1.2% | ||
| Q3 24 | -133.2% | -23.7% | ||
| Q2 24 | -198.2% | -14.8% | ||
| Q1 24 | -252.9% | -36.5% |
资本支出强度DNAPLBY
| Q4 25 | 0.0% | 0.8% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.1% | 1.4% | ||
| Q1 25 | 15.8% | 0.1% | ||
| Q4 24 | 31.3% | 1.7% | ||
| Q3 24 | 16.9% | 1.5% | ||
| Q2 24 | 48.1% | 2.6% | ||
| Q1 24 | 17.7% | 2.1% |
现金转化率DNAPLBY
| Q4 25 | — | 0.39× | ||
| Q3 25 | — | 22.02× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
PLBY
| Transferred At Point In Time | $22.2M | 64% |
| Trademark Licensing | $6.5M | 19% |
| Related Party | $5.0M | 14% |
| Other | $1.1M | 3% |
